[1]
|
M. D. Obritsch, D. N. Fish, R. MacLaren and R. Jung, “Nosocomial Infections Due to Multidrug-Resistant Pseudomonas aeruginosa: Epidemiology and Treatment Options,” Pharmacotherapy, Vol. 25, No. 10, 2005, pp. 1353-1364.
doi:10.1592/phco.2005.25.10.1353
|
[2]
|
T. Strateva and D. Yordanov, “Pseudomonas aeruginosa— A Phenomenon of Bacterial Resistance,” Journal of Medical Microbiology, Vol. 58, No. 9, 2009, pp. 1133-1148.
doi:10.1099/jmm.0.009142-0
|
[3]
|
H. P. Hahn, “The Type-4 Pilus Is the Major Virulence-Associated Adhesin of Pseudomonas aeruginosa,” Gene, Vol. 192, No. 1, 1997, pp. 99-108.
doi:10.1016/S0378-1119(97)00116-9
|
[4]
|
L. L. Blackwood, R. M. Stone, B. H. Iglewski and J. E. Pennington, “Evaluation of Pseudomonas aeruginosa Exotoxina and Elastase as Virulence Factors in Acute Lung Infection,” Infection and Immunity, Vol. 39, No. 1, 1983, pp. 198-201.
|
[5]
|
R. H. George, “Pseudomonas Infections in Cystic Fibrosis,” Archives of Disease in Childhood, Vol. 62, pp. 438-439. doi:10.1136/adc.62.5.438
|
[6]
|
R. Mittal, S. Sharma, S. Chhibber and K. Harjai, “A Time Course Study of Production of Virulence Factors by Biofilms of Pseudomonas aeruginosa,” American Journal of Biomedical Sciences, Vol. 1, No. 3, 2009, pp. 178-187.
doi:10.5099/aj090300178
|
[7]
|
R. E. W. Hancock and D. P. Speert, “Antibiotic Resistant in Pseudomonas aeruginosa: Mechanisms and Impact on Treatment,” Drug Resistance Updates, Vol. 3, No. 4, 2000, pp. 247-255. doi:10.1054/drup.2000.0152
|
[8]
|
E. Paramythiotou, J. C. Lucet, J. F. Timsit, D. Vanjak, C. Paugam-Burtz, J. L. Trouillet, S. Belloc, N. Kassis, A. Karabinis and A. Andremont, “Acquisition of Multidrug-Resistant Pseudomonas aeruginosa in Patients in Intensive Care Units: Role of Antibiotics with Antipseudomonal Activity,” Clinical Infectious Diseases, Vol. 38, No. 5, 2004, pp. 670-677. doi:10.1086/381550
|
[9]
|
V. Aloush, S. Navon-Venezia, Y. Seigman-Igra, S. Cabili and Y. Carmeli, “Multidrug-Resistant Pseudomonas aeruginosa: Risk Factors and Clinical Impact,” Antimicrob Agents and Chemotherapy, Vol. 50, No. 1, 2006, pp. 43-48. doi:10.1128/AAC.50.1.43-48.2006
|
[10]
|
D. L. Paterson, “The Epidemiological Profile of Infections with Multidrug-Resistant Pseudomonas aeruginosa and Acinetobacter Species,” Clinical Infectious Diseases, Vol. 43, Suppl. 2, 2006, pp. S43-S48.
doi:10.1086/504476
|
[11]
|
S. Cabili and Y. Carmeli, V. Aloush, S. Navon-Venezia and Y. Seigman-Igra, “Multidrug-Resistant Pseudomonas aeruginosa: Risk Factors and Clinical Impact Antimicrob,” Antimicrobial Agents and Chemotherapy, Vol. 50, No. 1, 2006, pp. 43-48.
doi:10.1128/AAC.50.1.43-48.2006
|
[12]
|
E. Paramythiotou, J.-C. Lucet, J.-F. Timsit, D. Vanjak, C. Paugam-Burtz, J.-L. Trouillet, S. Belloc, N. Kassis, A. Karabinis and A. Andremont, “Acquisition of Multidrug-Resistant Pseudomonas aeruginosa in Patients in Intensive Care Units: Role of Antibiotics with Antipseudomonal Activity,” Clinical Infectious Diseases, Vol. 38, No. 5, 2004, pp. 670-677. doi:10.1086/381550
|
[13]
|
I. Yoshida, T. Fujimura, Y. Itoh, M. Tachibana, M. Kaku, K. Kanemitsu, C. Takahashi, J. Shiotani, Y. Ono, H. Baba, S. Matsuo, S. Asari, K. Matsuoka, N. Kusano, M. Nose, T. Saikawa, K. Hiramatsu, S. Kohno, Y. Hirakata, N. Yamane, I. Nakasone and Y. Yamano, “Antimicrobial Susceptibility of Clinical Isolates of Aerobic Gram-Negative Bacteria in 2004,” Japanese Journal of Chemotherapy, Vol. 56, No. 5, 2008, pp. 562-579.
|
[14]
|
N. Abe, M. Komatsu, M. Iwasaki, Y. Nagasaka, S. Fu-kuda and S. Matsuo, “In Vitro Activity of Antimicrobial Agents against Clinical Isolates of Pseudomonas aeruginosa,” The Japanese Journal of Antibiotics, Vol. 58, No. 5, 2005, pp. 445-451.
|
[15]
|
A. Kanayama, M. Kida, T. Iyoda, K. Matsuzaki, S. Shibuya, M. Hasegawa, T. Saika, F. Ikeda and I. Kobayashi, “Annual Changes in Drug Susceptibility of Pseudomonas aeruginosa Isolated from Blood and Other Clinical Specimens,” Japanese Journal of Chemotherapy, Vol. 58, No. 1, 2010, pp. 7-13.
|
[16]
|
D. C. Hooper, “Fluoroquinolone Resistance among Gram-Positive Cocci,” The Lancet Infectious Diseases, Vol. 2, No. 9, 2002, pp. 530-538.
doi:10.1016/S1473-3099(02)00369-9
|
[17]
|
X.-S. Pan, J. Ambler, S. Mehtar and L. M. Fisher, “Involvement of Topoisomerase IV and DNA Gyrase as Ciprofloxacin Targets in Streptococcus pneumonia,” Antimicrobial Agents and Chemotherapy, Vol. 40, No. 10, 1996, pp. 2321-2326.
|
[18]
|
L. M. Weige, C. D. Steward and F. C. Tenover, “gyrA Mutations Associated with Fluoroquinolone Resistance in Eight Species of Enterobacteriaceae,” Antimicrobial Agents and Chemotherapy, Vol. 42, No. 10, 1998, pp. 2661-2667.
|
[19]
|
R. M. Salma, F. A. Dabboussi, I. O. Kassaa, R. H. Khudary and M. M. Hamze, “GyrA and ParC Mutations in Quinolone-Resistant Clinical Isolates of Pseudomonas aeruginosa from Nini Hospital in North Lebanon,” Journal of Infection and Chemotherapy, Vol. 19, No. 1, 2013, pp. 77-81.
|
[20]
|
J. Kriengkauykiat, E. Porter, O. Lomovskaya and A. Wong-Beringer, “Use of an Efflux Pump Inhibitor to Determine the Prevalence of Efflux Pump-Mediated Fluoroquinolone Resistance and Multidrug Resistance in Pseudomonas aeruginosa,” Antimicrobial Agents and Chemotherapy, Vol. 49, No. 2, 2005, pp. 565-570.
doi:10.1128/AAC.49.2.565-570.2005
|
[21]
|
M. Nakano, T. Deguchi, T. Kawamura, M. Yasuda, M. Kimura, Y. Okano and Y. Kawada, “Mutations in the gyrA and parC Genes in Fluoroquinolone-Resistant Clinical Isolates of Pseudomonas aeruginosa,” Antimicrobial Agents and Chemotherapy, Vol. 41, No. 10, 1997, pp. 2289-2291.
|
[22]
|
H. Mouneimné, J. Robert, V. Jarlier and E. Cambau, “Type II Topoisomerase Mutations in Ciprofloxacin-Resistant Strains of Pseudomonas aeruginosa,” Antimicrobial Agents and Chemotherapy, Vol. 43, No. 1, 1999, pp. 62-66.
|
[23]
|
P. G. Higgins, A. C. Fluit, D. Milatovic, J. Verhoef and F.-J. Schmitz, “Mutations in GyrA, ParC, MexR and NfxB in Clinical Isolates of Pseudomonas aeruginosa,” International Journal of Antimicrobial Agents, Vol. 21, No. 5, 2003, pp. 409-413. doi:10.1016/S0924-8579(03)00009-8
|
[24]
|
G. G. Zhanel, J. A. Karlowsky, M. H. Saunders, et al., “Development of Multiple Antibiotic-Resistant (MAR) Mutants of Pseudomonas aeruginosa after Serial Exposure to Fluoroquinolones,” Antimicrobial Agents and Chemotherapy, Vol. 39, No. 2, 1995, pp. 489-495.
doi:10.1128/AAC.39.2.489
|